Pulse Biosciences, Inc. (PLSE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on September 15, 2026. The filing reports a significant clinical milestone regarding the Company's nPulse™ Vybrance™ Percutaneous Electrode System, a device designed for the treatment of symptomatic benign thyroid nodules.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical development event and does not contain financial statements or updated financial data.
Material Changes and Clinical Milestones
- Study Completion: The Company announced the completion of patient enrollment in the PRECISE-BTN clinical study.
- Enrollment Expansion: The study was expanded from an original design of 50 patients to 100 patients.
- Timeline: All 100 patients were enrolled across three U.S. clinical sites (Sarasota Memorial Health Care System, NYU Langone Health, and Weill Cornell Medicine) within approximately 12 months.
- Follow-up Status: The first patient enrolled in the study has completed their final 12-month follow-up visit.
- Study Endpoints: The protocol tracks safety, targeted nodule volume reduction, symptomatic relief, hormone normalization, and quality of life improvements at one, three, six, and twelve months post-procedure.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future financial performance, or specific risk factors beyond the inherent nature of clinical trials. The primary focus is the successful execution of the enrollment phase and the initiation of long-term follow-up data collection.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for additional details on the study design.
- Monitor future filings for the release of primary endpoint data, particularly the 12-month results for the full cohort.
- Review upcoming quarterly reports (10-Q) or annual reports (10-K) for any financial impact related to the study expansion or operational costs.
- Confirm the regulatory pathway and FDA interaction status following the completion of enrollment.